176 related articles for article (PubMed ID: 18824451)
1. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Nanda A; Dias-Santagata DC; Stubbs H; O'Hara CJ; Zaner KS; Lynch TJ; Willers H
Clin Lung Cancer; 2008 Sep; 9(5):285-7. PubMed ID: 18824451
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Olmez I; Donahue BR; Butler JS; Huang Y; Rubin P; Xu Y
Lung Cancer; 2010 Nov; 70(2):174-9. PubMed ID: 20207442
[TBL] [Abstract][Full Text] [Related]
4. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
Wang S; Liao Z; Wei X; Liu HH; Tucker SL; Hu CS; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1399-407. PubMed ID: 16997503
[TBL] [Abstract][Full Text] [Related]
7. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Zhuang H; Yuan Z; Chang JY; Wang J; Pang Q; Zhao L; Wang P
J Thorac Oncol; 2014 Jun; 9(6):882-5. PubMed ID: 24828665
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
9. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
[TBL] [Abstract][Full Text] [Related]
10. New molecular targeted therapies integrated with radiation therapy in lung cancer.
Provencio M; Sánchez A; Garrido P; Valcárcel F
Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Cho BC; Im CK; Park MS; Kim SK; Chang J; Park JP; Choi HJ; Kim YJ; Shin SJ; Sohn JH; Kim H; Kim JH
J Clin Oncol; 2007 Jun; 25(18):2528-33. PubMed ID: 17577030
[TBL] [Abstract][Full Text] [Related]
12. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW; Choy H
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy.
Song CH; Pyo H; Moon SH; Kim TH; Kim DW; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):651-8. PubMed ID: 20207499
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
15. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
16. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Choy H; Yee L; Cole BF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
19. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Um SJ; Lee SK; Yang DK; Son C; Roh MS; Kim KN; Lee KN; Choi PJ
Clin Respir J; 2009 Jul; 3(3):181-4. PubMed ID: 20298401
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]